drugset / Trial / NCT00772304

Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis

NCT00772304

Phase 4 Completed 102 enrolled Alcon Research
RandomizedSingle-groupDouble-blindTreatment

Summary

To compare patient perceptions of the sensory attributes, including taste and aftertaste, of Olopatadine relative to azelastine when administered as a single dose in patients with allergic rhinitis.

Timeline

Start
2008-10
Primary completion
2008-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Azelastine Small molecule 137 ug Intranasal
Subject Olopatadine Other / unclassified 0.6 % Intranasal

Indications